Compound Radar

Iovance Biotherapeutics, Inc. (IOVA) Stock Analysis

United States · Healthcare / Biotechnology

Price $8.70
Market cap $3.94B
Next earnings Nov 5, 2026
Entry status Wait

Last updated Sep 8, 2026

Health Check

Last analyzed Sep 7, 2026

55
55/100 Acceptable
  • Financial Health 55
  • Profitability 70
  • Business Quality 50
  • Balance Sheet 55
  • Cash Flow 25

Why this rating?

Health 55/100 — Acceptable

Strongest Profitability 70/100
Softest Cash Flow 25/100
Wait

Entry timing is weak right now. Quality may be fine; the setup is not.

Company overview

Iovance Biotherapeutics, Inc. (IOVA) is a Biotechnology company in the Healthcare sector. Compound Radar rates Iovance Biotherapeutics, Inc. 55/100 (Acceptable) due to solid business quality and strong revenue growth.

Investment profile

  • Quality Moderate
  • Growth Strong
  • Balance Sheet Unknown

Financial highlights

Valuation

  • Forward P/E -30.28
  • EV/Revenue 11.48

Profitability

  • Revenue Growth 65.7%
  • Gross Margin 48.4%
  • Operating Margin -52.3%
  • Net Margin -89.1%
  • ROE -40.4%

Financial strength

  • Cash $297.67M
  • Debt $46.00M
  • Net Cash $251.67M
  • Free Cash Flow $-336.24M
  • Current Ratio 4.35

Similar companies

Peers in Biotechnology, ranked by Financial Health.

Company Ticker
Price Current price

Latest quoted price for the name. Helps anchor the setup in today’s market level.

Health Entry

View all in Biotechnology →

FAQ

How Compound Radar scores and tracks Iovance Biotherapeutics, Inc. (IOVA).

View Methodology & FAQ →